Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Interest & Investment Income (2019 - 2025)

Historic Interest & Investment Income for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $6.2 million.

  • BridgeBio Pharma's Interest & Investment Income rose 8929.0% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 1135.91%. This contributed to the annual value of $17.2 million for FY2024, which is 437.41% down from last year.
  • BridgeBio Pharma's Interest & Investment Income amounted to $6.2 million in Q3 2025, which was up 8929.0% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Interest & Investment Income registered a high of $6.2 million during Q3 2025, and its lowest value of $182000.0 during Q4 2021.
  • Over the past 5 years, BridgeBio Pharma's median Interest & Investment Income value was $3.9 million (recorded in 2025), while the average stood at $3.1 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 7970.12% in 2021, then soared by 214835.16% in 2022.
  • BridgeBio Pharma's Interest & Investment Income (Quarter) stood at $182000.0 in 2021, then soared by 2148.35% to $4.1 million in 2022, then skyrocketed by 36.31% to $5.6 million in 2023, then dropped by 16.05% to $4.7 million in 2024, then skyrocketed by 33.23% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $3.9 million for Q2 2025, and $5.4 million during Q1 2025.